Neuberger Berman Group LLC Fibrogen Inc Transaction History

Neuberger Berman Group LLC

9 transactions

Quarter	Operation	Price Per share	shares change	shares Held
Q4 2023 Nov 14, 2024	BUY	$0.38 - $0.91 $10,146 - $24,297	26,701 New	26,701 $23,000
Q4 2023 Feb 09, 2024	BUY	$0.38 - $0.91 $5,292 - $12,673	13,927 Added 109.03%	26,701 $23,000
Q3 2023 Nov 14, 2023	BUY	$0.79 - $2.83 $10,091 - $36,150	12,774 New	12,774 $10,000
Q4 2020 Feb 10, 2021	SELL	$37.09 - $48.97 $287,447 - $379,517	-7,750 Closed	0 $0
Q3 2020 Nov 12, 2020	BUY	$40.47 - $45.5 $313,642 - $352,625	7,750 New	7,750 $318,000
Q3 2019 Nov 13, 2019	SELL	$36.98 - $48.45 $240,369 - $314,925	-6,500 Closed	0 $0
Q2 2019 Aug 13, 2019	SELL	$35.13 - $55.53 $63,234 - $99,954	-1,800 Reduced 21.69%	6,500 $294,000
Q1 2019 May 13, 2019	SELL	$42.83 - $59.91 $72,811 - $101,847	-1,700 Reduced 17.0%	8,300 $451,000
Q4 2018 Feb 12, 2019	BUY	$37.97 - $60.16 $379,700 - $601,600	10,000 New	10,000 $463,000

47.1M

387K

672K

Ticker FGEN
Exchange NASDAQ
Sector Healthcare
Industry Biotechnology
Shares Outstandng 93,741,200
Market Cap $31.9M
Description
FibroGen, Inc., a biopharmaceutical company, discovers, develops, and commercializes therapeutics to treat serious unmet medical needs. The company is developing Roxadustat, an oral small molecule inhibitor of hypoxia inducible factor prolyl hydroxylases, which has completed Phase III clinical development for the treatment of anemia in chronic k...

Get notified when there are updates to the investment portfolio of Neuberger Berman Group LLC, based on Form 13F filings with the SEC.

Stay updated on Neuberger Berman Group LLC with notifications on news.